NCT07739784 This Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling.
| NCT ID | NCT07739784 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Condition | Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 352 participants |
| Start Date | 2026-02-25 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 352 participants in total. It began in 2026-02-25 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn whether personality traits are related to eye side effects from glaucoma medications in adults who currently use or previously used these medications. The main questions this study aims to answer are: Are certain personality traits associated with the occurrence or severity of eye side effects from glaucoma medications? Do personality traits differ between people who experience these side effects and those who do not? Participants will complete a questionnaire that measures five personality traits: openness, conscientiousness, extraversion, agreeableness, and neuroticism. They will also provide basic demographic information. The researchers will review participants' medical records to collect information about their glaucoma medications and any related eye side effects, including the type and frequency of side effects and whether treatment was changed because of them. Participation involves one session lasting approximately 30 minutes. Questionnaires may be completed securely online or in person at the clinic. The study will include approximately 352 adults. No treatment will be assigned or changed as part of this study.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Diagnosis of glaucoma. * Current or previous treatment with one or more glaucoma medications. * Able to provide informed consent. * Able to complete the study questionnaires in English or French. Exclusion Criteria: * Uncontrolled anxiety or depression that was present before glaucoma medication treatment began. * Unable to provide informed consent. * Unable to complete the study questionnaires in English or French.
Contact & Investigator
Hady Saheb, MD MPH
PRINCIPAL INVESTIGATOR
MUHC RI
Frequently Asked Questions
Who can join the NCT07739784 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07739784 currently recruiting?
Yes, NCT07739784 is actively recruiting participants. Contact the research team at ana.ramirezhernandez@mail.mcgill.ca for enrollment information.
Where is the NCT07739784 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT07739784 clinical trial?
NCT07739784 is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. The principal investigator is Hady Saheb, MD MPH at MUHC RI. The trial plans to enroll 352 participants.